. 2018 Oct 17;10:4695–4708. doi: 10.2147/CMAR.S178271

Table 1.

Main characteristics of eligible studies in the meta-analysis

Study, year	Disease type	Country	Study type	Included period	No. of cases	Male/ female	Age (years)	Survival type	Cutoff value	Cutoff selection	Follow- up	MVA	NOS score

Zhang et al 2015²⁴	UTCC	China	R	2006–2008	187	85/102	median: 70	OS, CSS	1.45	ROC	≥5 years	yes	7
Liu et al 2016²⁵	BC	China	R	2000–2013	296	250/46	mean: 61.71	CSS, RFS	1.6	ROC	≥5 years	yes	7
He et al 2017³³	RCC	China	R	2000–2012	895	600/295	mean: 51.44	OS	1.47	ROC	≥5 years	yes	8
Liu et al 2017²⁶	BC	China	R	2009–2013	189	165/24	NA	OS, PFS, CSS	1.55	ROC	≥5 years	yes	7
Koparal et al 2018²³	RCC	Turkey	R	2010–2016	162	102/60	mean:56.5	OS, DFS	1.4	ROC	≥5 years	yes	6
Niwa et al 2018³²	BC	China	R	2000–2015	364	294/70	median: 71	RFS, PFS	1.6	NA	≥5 years	yes	8
Shang et al 2018³⁴	BC	China	R	2004–2011	470	354/188	median: 70	OS, CSS	1.68	ROC	≥5 years	yes	8
Fukushima et al 2018³¹	UTCC	Japan	R	2003–2016	105	74/31	median: 74	OS, DFS	1.24	ROC	≥5 years	yes	6

Abbreviations: BC, bladder carcinoma; CSS, cancer-specific survival; DFS, disease-free survival; MVA, multivariate analysis; NA, not available; NOS, Newcastle–Ottawa Scale; OS, overall survival; PFS, progression-free survival; R, retrospectively; RCC, renal cell carcinoma; RFS, recurrence-free survival; ROC, receiver operating characteristic curve; UTCC, upper tract urothelial carcinoma